SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- The GLP-1 Paradox in Colorectal Cancer (Medscape)
- The most pressing workforce issues for 103 healthcare leaders (Becker’s Healthcare)
- FDA-cleared GI test detects ‘most likely causes’ of diarrheal syndromes (Healio)
- A path forward: women in gastroenterology (Gastrointestinal Endoscopy)
- 5 Gastroenterology Headlines You Missed in February 2026 (HCP Live)
- Endoluminal Robotics – what it really is (How to Startup in MedTech)
- AI in GI: A Humanist Approach (GI & Endoscopy News)
- Gastroenterology and private equity in 2026: 5 notes (Becker’s GI & Endoscopy)
